TB deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.

Civil society networks in India call for the Ministry of Health and Family Welfare and the National TB Elimination Program to take urgent action.

Less than half of required funding has been provided globally with dramatic consequences as hundreds of thousands more die from TB.

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Global Fund Results Report reveals COVID-19 devastating impact on HIV, TB and malaria programs.

Take a short survey and help evaluate the first 10 years of the Global TB CAB!